CIBERTERRITÓRIOS DE RESISTÊNCIA FEMININA: MÍDIA, MEMÓRIA E AFETOS
Revista Gênero · 2026
DOI: 10.22409/4j7vdv02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Gênero, 2026. Verfasst von Tiago Negrão Andrade und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article analyzes how digital coloniality, intertwined with platform capitalism, reproduces and updates systems of racial, gendered, and epistemic exploitation targeting Black, Indigenous, quilombola, peripheral, travesti, and trans women. The study demonstrates that datafication and platformization operate as algorithmic extraction devices, turning racialized knowledge, aesthetics, and bodies into digital commodities while reinforcing historical hierarchies of colonialism and patriarchy. Methodologically, a critical approach is employed, combining decolonial theories and feminist studies to explore three dimensions: (1) the capture and commodification of these women’s cultural productions; (2) algorithmic racism and digital necropolitics, which control racialized bodies through invisibilization or hypervisibility; and (3) the creation of insurgent cyberterritories, where practices of technological sovereignty and disruption strategies challenge colonial infrastructures. The conclusion highlights that, although digital platforms perpetuate historical violence, the mapped resistances redefine the digital as a space of memory, autonomy, and decolonial futures.
Zitieren
APA
Andrade, T. N., & Gobbi, M. C. (2026). CIBERTERRITÓRIOS DE RESISTÊNCIA FEMININA: MÍDIA, MEMÓRIA E AFETOS. Revista Gênero. https://doi.org/10.22409/4j7vdv02
Vancouver
Andrade TN, Gobbi MC. CIBERTERRITÓRIOS DE RESISTÊNCIA FEMININA: MÍDIA, MEMÓRIA E AFETOS. Revista Gênero. 2026. doi:10.22409/4j7vdv02
BibTeX
@article{Andrade2026,
author = {Andrade, Tiago Negrão and Gobbi, Maria Cristina},
title = {CIBERTERRITÓRIOS DE RESISTÊNCIA FEMININA: MÍDIA, MEMÓRIA E AFETOS},
journal = {Revista Gênero},
year = {2026},
doi = {10.22409/4j7vdv02}
}
EUVIMED